We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug discovery and development. Team members have invented and developed drugs that are approved for cancer treatment. Our approach to eradicating cancer is distinct from the current standard of care. Current approaches involve single agent single action drugs that either inhibit cancer cell growth or inhibit immunosuppression, and hence, they are ineffective. These drugs are combined in a bid to improve efficacy. But combination leads to toxicity, poor efficacy, and high cost. We are developing single agent dual action treatments inhibiting both cancer growth and immunosuppression. We are not targeting the immune checkpoint axis. Our approach will be effective for cancer patients that failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4 etc..